Albanese A, Stanhope R
Institute of Child Health, London, UK.
Horm Res. 1993;39(1-2):8-12. doi: 10.1159/000182687.
Twenty-five short children (6F, 19M) with intrauterine growth retardation were treated with daily subcutaneous injections of biosynthetic human growth hormone for 4 years. The treatment was commenced at a chronological age of 6.3 years (range 2.1-9.8). Eighteen of the patients had major dysmorphic signs of Russell-Silver syndrome. During the first year they were randomised into two groups treated with either 15 or 30 IU of growth hormone/m2/week. The higher dose was administered to all the children after the first year of the trial. After the initial increase in growth velocity SDS (greater in those treated with the higher dose regimen), there was a progressive decrease although with values significantly higher than pretreatment levels (p < 0.02) in both groups. However there was no improvement in height SDS for bone age after 4 years. The triceps and skinfold thickness showed a decrease during the first years followed by a gradual increase. The body mass index improved during the 4 years although showing no difference between the two treatment groups. There was no alteration in thyroid function or metabolic indices (glucose or lipid homeostasis) during the study.
25名宫内生长迟缓的矮小儿童（6名女性，19名男性）接受了为期4年的每日皮下注射生物合成人生长激素治疗。治疗开始时的实足年龄为6.3岁（范围2.1 - 9.8岁）。其中18名患者有Russell-Silver综合征的主要畸形体征。在第一年，他们被随机分为两组，分别接受15或30国际单位/平方米/周的生长激素治疗。试验第一年结束后，所有儿童均接受较高剂量治疗。在生长速度标准差最初增加后（高剂量治疗方案组增加更明显），尽管两组的值均显著高于治疗前水平（p < 0.02），但生长速度标准差仍逐渐下降。然而，4年后骨龄的身高标准差并无改善。三头肌和皮褶厚度在最初几年下降，随后逐渐增加。4年间体重指数有所改善，但两组之间无差异。研究期间甲状腺功能或代谢指标（葡萄糖或脂质稳态）无变化。
